Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical ...

Multiple bidders are likely to submit offers for the DNA data bank and other assets of bankrupt genetic-testing firm 23andMe, ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...